Ascelia Pharma AB
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Oncoral is initially developed for the treatment of gastric cancer, a cancer form with unmet needs and the opportunity for Orphan Drug status in the US and Europe. Following successful Phase 1 results, Phase 2 clinical development for Oncoral is in preparation. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info: